癌症检查点治疗的风湿性免疫相关不良事件:一种新疾病实体的病例系列
该病例系列报告了18个月内风湿科评估的15例风湿性免疫相关不良事件(irAEs)患者,其中13例无既往自身免疫病,2例已确诊自身免疫病。irAEs包括炎性关节炎、干燥综合征、风湿性多肌痛样症状和肌炎,所有病例需糖皮质激素,3例需生物制剂,除5例外其余患者免疫治疗暂时或永久停止。
要点
- 风湿性irAEs表现多样,包括炎性关节炎、干燥综合征、风湿性多肌痛样症状和肌炎。
- 所有患者需糖皮质激素,3例需生物制剂,多数患者免疫治疗暂时或永久停止。
- 既往自身免疫病患者免疫治疗后出现疾病 flare。
核心结论
- 风湿性irAEs复杂,有时需额外免疫抑制治疗,并可能影响原发疾病的持续免疫治疗方案。
- 随着检查点抑制剂成为社区标准治疗,类似irAEs将日益多见。
研究设计与样本
- 18个月期间风湿科评估15例风湿性irAEs患者的病例系列。
- 13例无既往自身免疫病,2例已确诊自身免疫病并预防性转诊。
主要发现
- irAEs包括炎性关节炎、干燥综合征、风湿性多肌痛样症状和肌炎。
- 所有病例需糖皮质激素,3例需生物制剂。
- 除5例外,其余患者免疫治疗暂时或永久停止。
- 1例既往自身免疫病患者开始免疫治疗后出现 flare。
临床怎么用
- 风湿科医生应认识检查点抑制剂相关风湿性irAEs的多种表现。
- 管理可能需糖皮质激素或生物制剂,并可能需调整免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy of cancer with checkpoint inhibitors has been associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatic irAEs are infrequently reported and extensively described. Here, we report our experience over an 18-month period with 15 patients evaluated in the rheumatology department for rheumatic irAEs. We identified 13 patients without pre-existing autoimmune disease (AID) who subsequently developed rheumatic irAEs, and two with established AID referred pre-emptively. irAEs encountered included: inflammatory arthritis, sicca syndrome, polymyalgia rheumatica-like symptoms and myositis. All cases required glucocorticoids, and three required a biological agent. Rheumatic irAEs led to temporary or permanent cessation of immunotherapy in all but five patients. One patient with pre-existing AID experienced a flare after starting immunotherapy. Our findings underscore that rheumatic irAEs are complex, at times require additional immunosuppressive therapy, and may influence ongoing immunotherapy regimens for the primary disease. Similar irAEs will be increasingly seen as checkpoint inhibitors adopted as standard of care in the community.
引用
- Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017. PMID: 28405474. doi:10.1136/rmdopen-2016-000412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。